Study guide
17.3 Electron Transport Chain, ATP Synthesis & Metabolic Inborn Errors
APMLE Part I Basic Sciences Podiatry
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Lower Extremity Osteology
1.1 APMLE Part I Exam Structure, Policies & Scoring 1.2 Foot Osteology: Tarsals, Metatarsals, Phalanges & Sesamoids 1.3 Leg & Ankle Osteology: Tibia, Fibula & The Ankle Mortise 1.4 Pelvis, Femur & Patella Osteology: Landmarks & Biomechanics
2 Chapter 2: Lower Extremity Arthrology & Ligaments
2.1 Foot Articulations: Subtalar, Midtarsal, Lisfranc & Digital Joints 2.2 Talocrural (Ankle) & Knee Joints: Ligaments & Kinematics 2.3 Hip Joint & Pelvic Articulations: Capsular Structures & Dynamics
3 Chapter 3: Lower Extremity Myology & Compartments
3.1 Anterior & Lateral Compartments of the Leg 3.2 Superficial & Deep Posterior Compartments of the Leg 3.3 Plantar Layers & Intrinsic Musculature of the Foot 3.4 Thigh & Gluteal Musculature: Attachments & Innervations
4 Chapter 4: Lower Extremity Neurovascular & Topographical Anatomy
4.1 Lumbar & Sacral Plexuses, Peripheral Nerves & Dermatomes 4.2 Arterial Network, Venous Drainage & Lymphatics 4.3 Tarsal Tunnel, Femoral Triangle & Topographical Spaces
5 Chapter 5: Microbiology: Bacteriology, Zoonoses & Laboratory Methods
5.1 Gram-Positive Cocci & Bacilli in Podiatric Infections 5.2 Gram-Negative Bacilli & Opportunistic Pathogens 5.3 Anaerobic Pathogens & Diabetic Foot Infections 5.4 Bacterial Structure, Virulence Factors & Sterilization 5.5 Mycobacteria, Spirochetes, Mycoplasma & Zoonotic Infections 5.6 Antimicrobial Resistance, Susceptibility Testing, Specimen Handling & Vaccines
6 Chapter 6: Mycology, Virology, Parasitology & Clinical Immunology
6.1 Mycology: Dermatophytes, Onychomycosis & Systemic Mycoses 6.2 Clinically Relevant Viruses & Parasitic Infections 6.3 Innate & Adaptive Immunity Mechanisms 6.4 Hypersensitivity Reactions, Immunodeficiencies & Autoimmunity 6.5 Transplant & Tumor Immunology and Immunodiagnostic Methods
7 Chapter 7: General & Cellular Pathology
7.1 Cellular Injury, Adaptations & Cell Death Mechanisms 7.2 Acute vs Chronic Inflammation & Tissue Repair 7.3 Hemodynamic Disorders, Thrombosis, Embolism & Shock 7.4 Neoplasia, Oncogenes, Tumor Suppressors & Cutaneous Tumors
8 Chapter 8: Systemic & Podiatric Pathology
8.1 Atherosclerosis, Peripheral Artery Disease & Diabetic Microangiopathy 8.2 Osteoarthritis, Inflammatory Arthritides & Bone Infections 8.3 Neuropathic Disorders, Charcot Neuroarthropathy & Dermatopathology 8.4 Laboratory Diagnostics, Synovial Fluid & Biopsy Interpretation
9 Chapter 9: Organ-System Pathology
9.1 Anemias, Hemoglobinopathies, Leukemias & Immune Disorders 9.2 Cardiac & Pulmonary Pathology 9.3 Renal, Urogenital & Reproductive Pathology 9.4 Gastrointestinal, Hepatobiliary & Endocrine Pathology
10 Chapter 10: General Pharmacology, Autonomic Drugs & Toxicology
10.1 Pharmacokinetics, ADME & Receptor Dynamics 10.2 Cholinergic Agonists & Muscarinic/Nicotinic Antagonists 10.3 Adrenergic Agonists, Sympatholytics & Clinical Applications 10.4 Cardiovascular Pharmacology in Podiatric Patients 10.5 Drug Interactions, Adverse Effects, Pharmacogenomics & Toxicology
11 Chapter 11: Antimicrobial & Podiatric Therapeutics
11.1 Antibacterial Classes, Mechanisms & Resistances 11.2 Antifungal, Antiviral & Antiparasitic Therapeutics 11.3 NSAIDs, Opioids, Corticosteroids & Anti-Gout Agents 11.4 Local & General Anesthetic Pharmacology
12 Chapter 12: Systemic Pharmacology
12.1 Anticonvulsants, Antidepressants, Psychotropics & Skeletal Muscle Relaxants 12.2 Insulin & Noninsulin Glycemic Agents 12.3 Respiratory & Gastrointestinal Agents 12.4 DMARDs, Biologics, Antineoplastics & Immunosuppressants 12.5 Hormone Therapy, Bisphosphonates, Antihistamines, Growth Factors & Complementary Agents
13 Chapter 13: General Anatomy: Systemic Gross Anatomy & Neuroanatomy
13.1 Cranial Nerves, Head & Neck Anatomy 13.2 Thoracic Wall, Tracheobronchial Tree, Lungs & Mediastinum 13.3 Abdominal Wall, GI Viscera, Pelvis & Retroperitoneum 13.4 Vertebral Column, Spinal Cord & Upper Extremity Overview 13.5 Neuroanatomy: CNS Organization, Somatosensory & Motor Pathways
14 Chapter 14: Histology, Integument, Embryology & Genetics
14.1 Microscopic Anatomy: Epithelia, Connective Tissue, Muscle & Nerve 14.2 Integumentary System: Dermis, Appendages, Nail Unit & Cutaneous Receptors 14.3 Embryogenesis, Limb Morphogenesis & Postnatal Development 14.4 Medical Genetics & Structural Alterations in Aging
15 Chapter 15: Cellular, Neuromuscular & Cardiovascular Physiology
15.1 Membrane Potential, Ion Channels & Transport Mechanisms 15.2 Action Potentials, Synaptic Transmission & Muscle Contraction 15.3 Cardiac Electrophysiology, ECG & Hemodynamics 15.4 Blood Pressure Regulation, Poiseuille Law & Capillary Dynamics
16 Chapter 16: Organ-System Physiology: Respiratory, Renal, Endocrine, GI & Blood
16.1 Pulmonary Mechanics, Gas Exchange & Acid-Base Regulation 16.2 Renal Filtration, Tubular Transport & Fluid/Acid-Base Balance 16.3 Endocrine Regulation, Reproductive Hormones, Calcium & Bone 16.4 Gastrointestinal & Hepatobiliary Physiology 16.5 Hematology: Erythropoiesis, Leukocytes, Platelets & Coagulation 16.6 Exercise Physiology, Thermoregulation & Bone Mechanobiology
17 Chapter 17: Biochemistry: Proteins, Enzymes, Carbohydrates & Signaling
17.1 Amino Acid Chemistry, Protein Structure & Enzyme Kinetics 17.2 Glycolysis, Gluconeogenesis, Glycogen Metabolism & TCA Cycle 17.3 Electron Transport Chain, ATP Synthesis & Metabolic Inborn Errors 17.4 Hormones, Receptors, Second Messengers & Signal Transduction
18 Chapter 18: Biochemistry: Lipids, Molecular Genetics, Blood Chemistry & Nutrition
18.1 Fatty Acid Oxidation, Ketogenesis, Cholesterol & Lipoproteins 18.2 Nucleotide Metabolism, DNA Replication, Transcription, Translation & Repair 18.3 Vitamins, Micronutrients & Inborn Errors of Metabolism 18.4 Blood Chemistry: Heme Metabolism, Hemoglobin & Plasma Proteins 18.5 Nutrition: Energy Balance, Glycemic Index, Fed-Fast Cycle & Free Radicals
17.3 Electron Transport Chain, ATP Synthesis & Metabolic Inborn Errors
Key Takeaways Explain This Topic AI
The Chemiosmotic Hypothesis (Mitchell) couples electron transport through Complexes I, III, and IV to active proton translocation from the mitochondrial matrix into the intermembrane space, generating an electrochemical proton gradient (proton-motive force) that drives ATP synthesis via Complex V (ATP synthase).
The respiratory complexes exhibit specific stoichiometric proton pumping: Complex I pumps 4 H+, Complex II pumps 0 H+ (oxidizing FADH2 via succinate dehydrogenase), Complex III pumps 4 H+, and Complex IV pumps 2 H+ while reducing O2 to H2O; mobile carriers Coenzyme Q and Cytochrome c shuttle electrons between complexes.
Inhibitors of electron transport directly arrest proton pumping and oxygen consumption: Rotenone inhibits Complex I, Antimycin A inhibits Complex III, Cyanide and carbon monoxide inhibit Complex IV (cyanide is treated with hydroxocobalamin or nitrites plus thiosulfate; carbon monoxide with 100% or hyperbaric oxygen), and Oligomycin blocks the F0 pore of Complex V. Uncouplers (2,4-DNP, high-dose aspirin, UCP-1/thermogenin) dissipate the proton gradient, collapsing ATP synthesis while stimulating maximal O2 consumption and lethal hyperthermia.
Inborn errors of carbohydrate metabolism include Galactosemia (Classic GALT deficiency causes Galactose-1-P and galactitol accumulation, infantile cataracts, hepatomegaly, failure to thrive, and life-threatening E. coli sepsis; GALK deficiency causes mild cataracts only) and Fructose disorders (benign Essential Fructosuria via fructokinase deficiency versus severe Hereditary Fructose Intolerance via aldolase B deficiency, which traps intracellular phosphate, halting glycogenolysis and gluconeogenesis).
The Pentose Phosphate Pathway (HMP Shunt) generates cytosolic NADPH (essential for fatty acid synthesis, respiratory burst, and glutathione reduction) and Ribose-5-phosphate; X-linked recessive Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency impairs NADPH generation, leaving erythrocytes unable to regenerate reduced glutathione (GSH) to detoxify peroxides, precipitating acute episodic hemolysis with Heinz bodies and bite cells upon exposure to oxidative triggers (fava beans, sulfa drugs, dapsone, primaquine, infections).
Last updated: October 2026
17.3 Electron Transport Chain, ATP Synthesis & Metabolic Inborn Errors
Independent Study Guide Notice: Independent study guide by ExamFinch. This educational resource is developed independently by ExamFinch and is not sponsored, endorsed, or affiliated with the National Board of Podiatric Medical Examiners (NBPME) or Meazure Learning.
Mitochondrial Architecture & The Chemiosmotic Hypothesis
Oxidative phosphorylation is the final common biochemical pathway of aerobic cellular respiration, taking place within specialized compartments of the mitochondrion . It couples the exergonic transfer of electrons from reducing equivalents (NADH and F A D H 2 FADH_2 F A D H 2 ) along the Electron Transport Chain (ETC) to the endergonic phosphorylation of ADP to generate ATP . Mitochondrial Compartments & Proton Pumping
- OUTER MEMBRANE: Freely permeable to small molecules (<5 kDa) via Porins
- ────────────────────────────────────────────────────────────────────────────
- INTERMEMBRANE SPACE: HIGH [H⁺] (Acidic pH ~7.0, Positive Charge)
- ▲ ▲ ▲
- 4 H⁺ 4 H⁺ 2 H⁺
- │ │ │
- INNER MEMBRANE: [Complex I] [Complex III] [Complex IV] [Complex V]
- (Cardiolipin-rich; │ │ │ │
- Impermeable to H⁺) └──> [CoQ] ──┘──>[Cyt c]──┘ │ H⁺ Flux
- ▲ ▼
- [Complex II] (ATP Synthase)
- ────────────────────────────────┼─────────────────────────────────┼─────────
- MITOCHONDRIAL MATRIX: Succinate ──> Fumarate ADP + Pi ──> ATP
- LOW [H⁺] (Alkaline pH ~7.8, Negative Charge)
- (Houses TCA cycle, Beta-oxidation, PDC, mtDNA, and Ribosomes)
- The Chemiosmotic Hypothesis (Peter Mitchell)
The mechanism coupling electron transport to ATP synthesis is defined by the Chemiosmotic Hypothesis :
Proton Pumping: As electrons transit down a series of oxidation-reduction complexes embedded in the inner mitochondrial membrane, the free energy released from these exergonic redox reactions drives the active pumping of protons ( H + H^+ H + ) from the mitochondrial matrix outward into the intermembrane space .
Proton-Motive Force ( Δ p \Delta p Δ p ): Because the inner mitochondrial membrane is strictly impermeable to protons (reinforced by the unique phospholipid cardiolipin ), an electrochemical proton gradient is established across the membrane. This proton-motive force consists of two components:
Electrical Potential ( Δ Ψ \Delta \Psi ΔΨ ): The matrix is negatively charged relative to the positive intermembrane space (~160 to 180 mV).
Chemical Gradient ( Δ p H \Delta pH Δ p H ): The intermembrane space is slightly acidic (pH ~7.0), while the matrix is alkaline (pH ~7.8).
ATP Synthesis: Protons can re-enter the matrix exclusively by passing through the designated proton channel of Complex V (ATP Synthase) . The thermodynamic dissipation of this proton gradient drives the mechanical rotation of ATP synthase, phosphorylating ADP and inorganic phosphate ( P i P_i P i ) into ATP .
The Respiratory Complexes (I through V) & Electron Flow
Electrons donated by NADH and F A D H 2 FADH_2 F A D H 2 traverse four respiratory complexes organized in order of increasing standard reduction potential ( E ∘ ′ E^{\circ'} E ∘ ′ ) , culminating in the reduction of molecular oxygen to water at Complex IV: Flow of Electrons in the ETC
- NADH ──> [Complex I] ──┐
- (Pumps 4 H⁺) │
- ├──> [Coenzyme Q] ──> [Complex III] ──> [Cytochrome c]
- FADH2 ─> [Complex II] ─┘ (Ubiquinone) (Pumps 4 H⁺) (Mobile Carrier)
- (Pumps 0 H⁺) │
- ▼
- [Complex IV]
- (Pumps 2 H⁺)
- │
- ▼
- 1/2 O2 ──> H2O
- 1. Complex I (NADH:Ubiquinone Oxidoreductase)
Accepts two high-energy electrons from matrix NADH , transferring them sequentially to Flavin Mononucleotide (FMN) and a series of Iron-Sulfur (Fe-S) centers , which ultimately reduce lipid-soluble Coenzyme Q (Ubiquinone) to ubiquinol ( Q H 2 QH_2 Q H 2 ).
Proton Translocation: Coupled to the transfer of 2 electrons, Complex I actively pumps 4 protons ( 4 H + 4 H^+ 4 H + ) from the matrix into the intermembrane space.
Specific Inhibitors: Blocked by the pesticide Rotenone , as well as the barbiturate Amobarbital .
2. Complex II (Succinate Dehydrogenase)
The only membrane-bound component of the TCA cycle. Catalyzes the oxidation of succinate to fumarate, transferring electrons to enzyme-bound FAD , which funnels them through Fe-S centers to Coenzyme Q .
Proton Translocation: Pumps ZERO protons ( 0 H + 0 H^+ 0 H + ) because the free-energy change of succinate oxidation is insufficient to drive proton translocation.
Consequence for ATP Yield: Because electrons from F A D H 2 FADH_2 F A D H 2 bypass Complex I and pump fewer total protons across the membrane, 1 mole of F A D H 2 FADH_2 F A D H 2 yields approximately 1.5 ATP , whereas 1 mole of NADH (entering at Complex I) yields approximately 2.5 ATP .
Specific Inhibitors: Competitively inhibited by Malonate (structural analog of succinate).
Coenzyme Q (Ubiquinone / CoQ10)
A small, highly hydrophobic, mobile quinone carrier dissolved within the lipid bilayer of the inner mitochondrial membrane. It accepts electrons from Complex I, Complex II, the glycerol-3-phosphate shuttle, and the electron-transferring flavoprotein (ETF) of fatty acid β \beta β -oxidation, shuttling them to Complex III.
3. Complex III (Cytochrome b c 1 bc_1 b c 1 Complex / Ubiquinol:Cytochrome c Oxidoreductase)
Accepts electrons from reduced ubiquinol ( Q H 2 QH_2 Q H 2 ) and transfers them through cytochromes b b b , c 1 c_1 c 1 , and the Rieske Fe-S center via the specialized two-step Q-Cycle , ultimately transferring single electrons to the mobile carrier Cytochrome c .
Proton Translocation: Actively pumps 4 protons ( 4 H + 4 H^+ 4 H + ) into the intermembrane space per electron pair.
Specific Inhibitors: Potently inhibited by Antimycin A (a piscicide/antibiotic).
Cytochrome c
A small, water-soluble peripheral hemoprotein loosely associated with the outer surface of the inner mitochondrial membrane within the intermembrane space. Serves as a single-electron mobile shuttle between Complex III and Complex IV.
Dual Role in Apoptosis: In response to intrinsic cellular injury or stress (e.g., DNA damage, ischemia), the pro-apoptotic proteins Bax and Bak oligomerize to form pores in the outer mitochondrial membrane. Cytochrome c leaks into the cytosol, binding Apaf-1 (Apoptotic Protease Activating Factor 1) to form the wheel-like apoptosome , which recruits and activates procaspase-9 to trigger executioner caspase-3 mediated programmed cell death.
4. Complex IV (Cytochrome c Oxidase)
Contains two heme moieties (cytochromes a a a and a 3 a_3 a 3 ) and two copper centers ( C u A Cu_A C u A and C u B Cu_B C u B ). It collects 4 electrons from four reduced Cytochrome c molecules and transfers them to terminal molecular oxygen ( O 2 O_2 O 2 ), reducing it to two molecules of water: O 2 + 4 H + + 4 e − ⟶ 2 H 2 O \text{O}_2 + 4H^+ + 4e^- \longrightarrow 2H_2O O 2 + 4 H + + 4 e − ⟶ 2 H 2 O
Proton Translocation: Actively pumps 2 protons ( 2 H + 2 H^+ 2 H + ) into the intermembrane space per pair of electrons transferred.
Inhibitors of Complex IV: Cyanide ( C N − CN^- C N − ) , Carbon Monoxide ( C O CO CO ) , Sodium Azide ( N a N 3 NaN_3 N a N 3 ) , and Hydrogen Sulfide ( H 2 S H_2S H 2 S ) bind tightly to the heme iron in cytochrome a 3 a_3 a 3 , arresting oxygen reduction, collapsing the proton gradient, and halting cellular ATP generation.
5. Complex V (ATP Synthase: F 0 F 1 F_0F_1 F 0 F 1 Complex)
A multi-subunit rotary molecular motor consisting of two functional domains:
F 0 F_0 F 0 Domain: Hydrophobic, membrane-spanning stalk containing the proton-translocating channel.
F 1 F_1 F 1 Domain: Spherical catalytic headpiece projecting into the mitochondrial matrix, composed of α 3 β 3 \alpha_3\beta_3 α 3 β 3 subunits that catalyze the synthesis of ATP from ADP and P i P_i P i .
Protons flowing down their electrochemical gradient through the F 0 F_0 F 0 channel drive the mechanical rotation of the central γ \gamma γ -stalk, inducing conformational changes in the F 1 F_1 F 1 catalytic heads to forge high-energy phosphoanhydride bonds.
Specific Inhibitors: Oligomycin binds directly to the F 0 F_0 F 0 subunit, physically occluding the proton channel. Because protons can no longer re-enter the matrix, the electrochemical gradient hyperpolarizes to an intolerable level, creating electrostatic back-pressure that secondarily halts the electron transport chain and oxygen consumption .
Inhibitors vs. Chemical Uncouplers of Oxidative Phosphorylation
A pivotal distinction on licensing examinations is differentiating between ETC Inhibitors and Chemical Uncouplers : ETC Inhibitors vs. Chemical Uncouplers Comparison
- PARAMETER ETC INHIBITORS CHEMICAL UNCOUPLERS
- ───────────────────────────────────────────────────────────────────────────────
- Primary Target Specific Complex (I - IV) Inner Membrane Permeability
- Proton Gradient COLLAPSES (Pumping Stops) COLLAPSES (Protons Leak In)
- Oxygen Consumption (O2) HALTS (Blocks Electron Flux) MAXIMALLY ACCELERATES
- ATP Synthesis HALTS HALTS
- Body Temperature Normal / Hypothermic SEVERE HYPERTHERMIA
- Examples Rotenone, Cyanide, CO, Azide 2,4-DNP, Aspirin, Thermogenin
- 1. Electron Transport Chain Inhibitors
Directly block electron transfer at a specific redox complex. Because electron transfer is obligatorily coupled to proton pumping, both proton pumping and oxygen consumption stop completely . ATP synthesis halts because the proton gradient is lost. Tissues switch to anaerobic glycolysis, producing severe lactic acidosis .
Cyanide Poisoning:
Binds ferric ( F e 3 + Fe^{3+} F e 3 + ) heme iron in cytochrome a 3 a_3 a 3 with high affinity, arresting Complex IV.
Clinical Presentation: Tissues cannot extract oxygen from the blood. Arterial and venous oxygen saturation remain virtually identical; venous blood appears bright cherry-red . Patients present with headache, vomiting, seizures, lactic acidosis, and an odor of bitter almonds on the breath.
Antidote Therapy: Rapid administration of Hydroxocobalamin (binds cyanide to form non-toxic cyanocobalamin, excreted in urine) OR a two-step regimen: Nitrites (Amyl nitrite / Sodium nitrite) to oxidize hemoglobin F e 2 + Fe^{2+} F e 2 + to methemoglobin ( F e 3 + Fe^{3+} F e 3 + ), which avidly traps cyanide away from Complex IV, followed immediately by Sodium Thiosulfate (allowing hepatic rhodanese to convert cyanomethemoglobin into water-soluble thiocyanate).
Carbon Monoxide (CO) Poisoning:
Binds ferrous ( F e 2 + Fe^{2+} F e 2 + ) heme iron in hemoglobin with >200-fold higher affinity than oxygen, causing competitive displacement and an allosteric leftward shift in the oxygen-hemoglobin curve (preventing oxygen delivery to tissues). Additionally, CO directly inhibits Complex IV in mitochondria.
Clinical Presentation: Headache, nausea, cherry-red skin coloration, normal P a O 2 PaO_2 P a O 2 on routine arterial blood gas, but markedly depressed actual oxygen content and elevated carboxyhemoglobin on co-oximetry. Treated with 100% normobaric or hyperbaric oxygen .
2. Chemical & Physiological Uncouplers
Mechanism: Increase the proton permeability of the inner mitochondrial membrane, allowing protons in the intermembrane space to leak directly back into the matrix without passing through Complex V (ATP Synthase) .
Metabolic Consequences:
The proton gradient is completely dissipated → \rightarrow → ATP synthesis halts .
Freed from the back-pressure of the proton gradient, electron transport down Complexes I through IV accelerates to its maximum possible rate → \rightarrow → Oxygen consumption ( O 2 O_2 O 2 ) reaches maximal levels .
The massive energy of substrate oxidation, no longer captured as ATP, is released entirely as uncontrolled HEAT .
High-Yield Uncoupling Agents:
2,4-Dinitrophenol (2,4-DNP): A lipophilic weak acid historically abused as an illicit rapid weight-loss agent. Carries protons across the inner membrane into the matrix. Produces rapid weight loss accompanied by severe, potentially fatal hyperthermia (distinct from the RYR1-mediated anesthetic reaction called malignant hyperthermia), profuse diaphoresis, tachycardia, tachypnea, and severe metabolic acidosis.
High-Dose Salicylates (Aspirin Overdose): In toxic overdoses, aspirin acts as an uncoupler of oxidative phosphorylation. Patients present with hyperthermia, tachypnea, and a classic mixed acid-base disorder ( respiratory alkalosis via direct medullary respiratory center stimulation followed by high anion gap metabolic acidosis via uncoupling and accumulation of organic acids).
Thermogenin (Uncoupling Protein 1, UCP-1): Endogenous physiological uncoupling protein expressed in the inner mitochondrial membrane of brown adipose tissue . Protons bypass ATP synthase to generate non-shivering thermogenesis, maintaining core body temperature in human neonates and hibernating mammals.
Complex / Agent Target / Mechanism Effect on Proton Gradient Effect on O 2 O_2 O 2 Consumption Effect on ATP Synthesis Clinical Correlation
- Rotenone Inhibits Complex I Decreased Decreased Decreased Pesticide exposure; experimental Parkinson model
- Malonate Inhibits Complex II Decreased Decreased Decreased Competitive inhibitor of succinate dehydrogenase
- Antimycin A Inhibits Complex III Decreased Decreased Decreased Piscicide; halts Q-cycle electron transfer
Cyanide ( C N − CN^- C N − ) Inhibits Complex IV ( F e 3 + Fe^{3+} F e 3 + ) Decreased Decreased Decreased Smoke inhalation; cherry-red venous blood; treated with hydroxocobalamin
Carbon Monoxide Inhibits Complex IV & Hb Decreased Decreased Decreased Carboxyhemoglobinemia; headache; treated with 100% O 2 O_2 O 2
Oligomycin Inhibits Complex V ( F 0 F_0 F 0 ) Increased (hyperpolarizes) Decreased Decreased Halts proton flux through ATP synthase stalk
2,4-DNP Uncoupler (proton leak) Dissipated (collapses) Maximal Increase Decreased Illicit weight-loss drug; severe hyperthermia
Aspirin (Toxic) Uncoupler (proton leak) Dissipated Increased Decreased Mixed respiratory alkalosis & metabolic acidosis
Thermogenin (UCP1) Physiological uncoupler Dissipated Increased Decreased Non-shivering thermogenesis in infant brown fat
Important
Inhibitor vs. Uncoupler Oxygen Signature:
If an agent stops ATP synthesis AND stops oxygen consumption , it is an ETC Complex Inhibitor (e.g., Cyanide, Rotenone, Antimycin A, Oligomycin).
If an agent stops ATP synthesis BUT maximizes oxygen consumption and generates extreme fever , it is an Uncoupler (e.g., 2,4-DNP, Aspirin toxicity, UCP-1).
Inborn Errors of Carbohydrate Metabolism: Galactose & Fructose
Inherited enzymatic defects in the metabolic assimilation of dietary disaccharides (lactose from milk; sucrose from cane sugar/fruits) produce severe infantile and pediatric pathology: Metabolism of Galactose and Fructose
- GALACTOSE METABOLISM FRUCTOSE METABOLISM
- ──────────────────── ───────────────────
- Lactose (Milk) ──> Glucose + Galactose Sucrose (Sugar) ──> Glucose + Fructose
- │ │
- GALK Deficiency ───X │ (Galactokinase) Fructokinase Def. ──X │ (Fructokinase)
- (Mild Cataracts) ▼ (Essential Fructosuria)▼
- Galactose-1-Phosphate Fructose-1-Phosphate
- │ │
- GALT Deficiency ───X │ (GALT) Aldolase B Def. ──X │ (Aldolase B)
- (CLASSIC GALACTOSEMIA)▼ (HEREDITARY FRUCTOSE)▼
- UDP-Galactose DHAP + Glyceraldehyde
- │ │
- ▼ ▼
- Glucose-1-Phosphate Glycolysis
- Galactosemia: Classic GALT vs. Galactokinase Deficiency
Dietary lactose is cleaved by intestinal lactase into glucose and galactose . Galactose enters hepatocytes to be phosphorylated:
Galactokinase (GALK) Deficiency:
Defect: Autosomal recessive deficiency of Galactokinase .
Pathophysiology: Galactose cannot be phosphorylated to galactose-1-P. Unphosphorylated galactose accumulates in tissues and is shunted by aldose reductase into galactitol , an osmotically active polyol alcohol.
Clinical Presentation: Mild, benign condition . Galactitol accumulates within the lens of the eye, drawing in water and producing bilateral infantile cataracts (loss of red reflex). No liver failure, no renal tubular dysfunction, and no intellectual disability. Galactose is excreted in the urine (positive reducing sugar).
Classic Galactosemia (GALT Deficiency):
Defect: Autosomal recessive deficiency of Galactose-1-Phosphate Uridylyltransferase (GALT) .
Pathophysiology: Ingestion of milk/formula leads to severe intracellular accumulation of toxic Galactose-1-Phosphate in hepatocytes, renal tubular cells, and the brain, accompanied by massive galactitol accumulation in the lens.
Clinical Presentation: Manifests within days to weeks of starting breast milk or cow's milk formula:
Profound failure to thrive, persistent vomiting, diarrhea, and dehydration.
Jaundice, hepatomegaly, and liver cirrhosis progressing to hepatic failure.
Bilateral "oil-droplet" cataracts .
Severe intellectual disability and speech deficits.
Pathognomonic Complication: Overwhelming, life-threatening neonatal Escherichia coli sepsis (galactose-1-phosphate impairs leukocyte bactericidal activity).
Diagnostic & Treatment: Clinitest detects reducing sugar in urine (glucose-dipstick negative); confirmation via erythrocyte GALT enzyme assay. Treatment: absolute, lifelong elimination of galactose and lactose from the diet.
Fructose Disorders: Essential Fructosuria vs. Hereditary Fructose Intolerance
Dietary sucrose (table sugar) is cleaved by sucrase into glucose and fructose . High-fructose corn syrup, honey, and fruits provide direct dietary fructose:
Essential Fructosuria:
Defect: Autosomal recessive deficiency of Fructokinase .
Clinical Presentation: Completely benign, asymptomatic metabolic anomaly . Fructose cannot be trapped intracellularly and is excreted harmlessly in the urine. Detected incidentally on routine pediatric screening when urine tests positive for reducing substances (Clinitest positive) but negative on glucose oxidase dipsticks.
Hereditary Fructose Intolerance (HFI):
Defect: Autosomal recessive deficiency of Aldolase B (Fructose-1,6-Bisphosphate Aldolase B) .
Pathophysiology: Ingested fructose is phosphorylated by fructokinase into Fructose-1-Phosphate (F-1-P) , which cannot be cleaved and accumulates rapidly within hepatocytes, renal proximal tubule cells, and enterocytes.
Phosphate Trapping Mechanism: Accumulating F-1-P sequesters intracellular inorganic phosphate ( P i P_i P i ), causing profound intracellular phosphate depletion . The lack of free P i P_i P i inhibits glycogen phosphorylase (completely halting glycogenolysis) and depresses ATP synthesis (inhibiting gluconeogenesis).
Clinical Presentation: Symptoms appear classically when an infant is weaned from breast milk/formula and introduced to complementary fruits, fruit juices, honey, or table sugar (around 4 to 6 months of age):
Profound, symptomatic hypoglycemia , diaphoresis, tremors, lethargy, and vomiting shortly after fructose ingestion.
Hepatosplenomegaly, jaundice, and progressive liver cirrhosis.
Proximal renal tubular acidosis ( Fanconi syndrome with aminoaciduria, phosphaturia, and metabolic acidosis).
Treatment: Strict, permanent dietary exclusion of fructose, sucrose, and sorbitol (sorbitol is metabolized to fructose via sorbitol dehydrogenase).
- Feature Galactokinase Deficiency Classic Galactosemia Essential Fructosuria Hereditary Fructose Intolerance
- Defective Enzyme Galactokinase (GALK) Galactose-1-P Uridylyltransferase (GALT) Fructokinase Aldolase B
- Accumulated Metabolite Galactitol Galactose-1-P & Galactitol Fructose Fructose-1-Phosphate
- Onset of Symptoms Infancy First days of milk feeding Asymptomatic Weaning to fruits / sucrose
- Severity Mild Severe, life-threatening Completely benign Severe, life-threatening
- Hypoglycemia None Mild None Severe, profound
- Hepatic Pathology None Jaundice, cirrhosis, failure None Jaundice, hepatomegaly, failure
- Cataracts Yes (Infantile) Yes (Oil-droplet) None None
Special Hallmark Isolated cataracts Neonatal E. coli sepsis Incidental reducing sugar Phosphate trapping; Fanconi synd.
- Urine Reducing Test Positive (Galactose) Positive (Galactose) Positive (Fructose) Positive (Fructose)
- The Pentose Phosphate Pathway & G6PD Deficiency
The Pentose Phosphate Pathway (PPP), also known as the Hexose Monophosphate (HMP) Shunt , is an alternative cytosolic pathway of glucose catabolism that branches from Glucose-6-Phosphate:
Location & Energy: Occurs entirely in the cytosol ; generates zero ATP .
Two Primary Physiological Functions:
Generation of NADPH: Nicotinamide adenine dinucleotide phosphate is utilized for reductive biosynthesis (fatty acids, cholesterol, bile acids, steroid hormones), the respiratory burst in neutrophils (NADPH oxidase), cytochrome P450 hydroxylation, and the maintenance of reduced glutathione (GSH) .
Generation of Ribose-5-Phosphate: Obligate substrate for the de novo biosynthesis of purine and pyrimidine nucleotides (DNA and RNA synthesis). Glutathione Defense Against Oxidative Stress
- [HMP SHUNT: G6PD] ──> Generates NADPH
- │
- ▼
- Glutathione Reductase: Converts GSSG (Oxidized) ──> 2 GSH (Reduced)
- │
- ▼
- Glutathione Peroxidase: Neutralizes H2O2 ────────> 2 H2O
- (Protects Erythrocyte Cell Membrane)
- The Oxidative & Non-Oxidative Phases
Oxidative Phase (Irreversible):
Glucose-6-Phosphate Dehydrogenase (G6PD): Oxidizes Glucose-6-P to 6-Phosphoglucono- δ \delta δ -lactone, generating 1 NADPH . This is the committed, rate-limiting enzyme of the pathway, stimulated by N A D P + NADP^+ N A D P + and inhibited by NADPH.
A second oxidation step by 6-phosphogluconate dehydrogenase yields a second NADPH , C O 2 CO_2 C O 2 , and Ribulose-5-phosphate.
Non-Oxidative Phase (Reversible):
Interconverts ribulose-5-phosphate into Ribose-5-P (nucleotides) or shunts excess pentoses back into glycolytic intermediates (Fructose-6-P and Glyceraldehyde-3-P).
Catalyzed by Transketolase , an enzyme that obligatorily requires Thiamine Pyrophosphate (TPP, Vitamin B 1 B_1 B 1 ) as a cofactor. Measuring erythrocyte transketolase activity before and after thiamine addition is the clinical gold standard for diagnosing thiamine deficiency.
Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency
Genetics & Epidemiology: X-linked recessive disorder; represents the most prevalent red blood cell enzymatic defect worldwide (>400 million individuals). High prevalence in populations of Mediterranean, African, and Middle Eastern ancestry, where carrier females enjoy partial protective resistance against severe malaria caused by Plasmodium falciparum .
Pathophysiology:
Mature erythrocytes possess no mitochondria and no nuclei; the HMP shunt is their sole biological source of NADPH .
NADPH is required by Glutathione Reductase to reduce oxidized glutathione disulfide (GSSG) back into two molecules of reduced glutathione (GSH) .
GSH is used by Glutathione Peroxidase to detoxify hydrogen peroxide ( H 2 O 2 H_2O_2 H 2 O 2 ) and reactive oxygen species into harmless water ( 2 GSH + H 2 O 2 ⟶ GSSG + 2 H 2 O 2\text{GSH} + \text{H}_2\text{O}_2 \longrightarrow \text{GSSG} + 2\text{H}_2\text{O} 2 GSH + H 2 O 2 ⟶ GSSG + 2 H 2 O ).
When G6PD is deficient, erythrocytes cannot replenish GSH. Exposure to oxidative stress causes hydrogen peroxide to oxidize the sulfhydryl groups of hemoglobin, causing hemoglobin to denature, cross-link, and precipitate into insoluble intracellular inclusions termed Heinz bodies .
As erythrocytes traverse the narrow endothelial slits of the splenic red pulp, resident macrophages pluck out the rigid Heinz bodies, excising a portion of the red cell membrane to yield pathognomonic bite cells (degmacytes) . The damaged, deformed erythrocytes undergo acute intravascular and extravascular hemolysis .
Clinical Triggers of Acute Hemolytic Episodes:
Infections: The most common clinical trigger (activated neutrophils generate massive H 2 O 2 H_2O_2 H 2 O 2 in the oxidative respiratory burst, which diffuses into erythrocytes).
Medications:
Antibiotics: Sulfonamides (Trimethoprim-sulfamethoxazole), Nitrofurantoin.
Antimycobacterial / Dermatological: Dapsone .
Antimalarials: Primaquine , Chloroquine.
Others: Rasburicase, high-dose Aspirin.
Foods: Ingestion of Fava beans ( Favism ; contains the oxidizing glucosides vicine and convicine; most severe in the Mediterranean G6PD variant).
Clinical Presentation: Two to three days following exposure to an oxidative trigger, the patient develops sudden fatigue, pallor, scleral icterus, dark red-brown "cola-colored" urine (hemoglobinuria), and back/flank pain. Laboratory evaluation reveals normocytic anemia, elevated reticulocyte count, indirect hyperbilirubinemia, elevated serum LDH, and severely depressed serum haptoglobin.
Diagnostic Pitfall: G6PD enzyme levels can test falsely normal during an acute hemolytic crisis because older, enzyme-depleted erythrocytes have already lysed, leaving behind younger reticulocytes with higher basal G6PD activity. Confirmatory testing must be repeated 2 to 3 months following resolution of the acute hemolytic episode.
Note
Podiatric Medical Implication of G6PD Deficiency: Podiatric physicians frequently treat severe diabetic foot infections, soft tissue abscesses, and osteomyelitis with broad-spectrum oral antibiotics, commonly Trimethoprim-Sulfamethoxazole (Bactrim) to eradicate MRSA. Before initiating sulfa antimicrobial therapy in high-risk demographic populations, checking for a history of G6PD deficiency is vital to avoid precipitating life-threatening acute hemolytic crises.